VIDEO: Recent ARASENS trial results are ‘practice-changing’ in prostate cancer
Click Here to Manage Email Alerts
Tanya Dorff, MD, section chief of the genitourinary disease program at City of Hope, spoke with Healio about results from the ARASENS trial presented at the 2022 ASCO Genitourinary Cancers Symposium.
The phase 3 trial assessed the addition of darolutamide to androgen deprivation therapy and docetaxel in patients with metastatic hormone-sensitive prostate cancer.
“The ARASENS trial is clearly practice-changing, especially once darolutamide gets the additional indication in metastatic hormone-sensitive prostate cancer," Dorff said, "It follows along the heels of multiple first-line studies.”
She added, “What’s really unique is that this is the first study that prospectively asked the question, ‘If all of our metastatic hormone-sensitive prostate cancer patients get upfront docetaxel, do they still benefit from [an androgen receptor]-targeted agent on top of that?’ And the answer was really a resounding yes.”
Collapse
Healio Interview
Smith MR, et al. Abstract 13. Presented at: ASCO Genitourinary Cancers Symposium; Feb. 17-19, 2022; San Francisco.
Click Here to Manage Email Alerts